Inventor · disambiguated record
Jingxuan Liu
Also filed as: LIU JINGXUAN
3 granted patents·9 pending applications·18 citations·filing 2017–2023
66Inventor score
Files withALNYLAM PHARMACEUTICALS INC12
Top patents by PatentIndex Score
12 records- 0194US11326166B1Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·3 cites·29 claims
- 0294US10934544B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·15 cites·23 claims
- 0384US12338439B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 24, 2025·0 cites·16 claims
- 0478US2024254482A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0572US2021246447A1Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0669US2022267767A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0767US2022411801A1XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0866US2018100150A1Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0960US2020208150A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1057US2022228151A1Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1155US2025283071A1Modified double stranded oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1254US2022228144A1SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jingxuan Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →